Jon Markman

Jon Markman

Jon Markman is the editor of Trader’s Advantage, a daily trading service that leverages his unique swing trading principles and aims to capture profits of 7% to 15% — and often much more with his options trades — in less than 90 days. By combining technical analysis with underlying fundamentals, Jon recommends beaten down stocks on the brink of reversal and powerful momentum stocks breaking out to new highs.

In CounterPoint Options Jon helps options traders lock in consistent profits from the volatility that rocks the market. At its heart is a proprietary trading system, Magnitude, that pinpoints indexes or sectors that have reached a critical inflection point — then translates that signal into profitable trades.

CounterPoint Options keeps volatility options trading very simple, focusing on the most popular, highly traded exchange-traded funds (ETFs) that are headed for a key reversal. Magnitude scans the market and allows subscribers to take advantage of these very liquid trading opportunities.

When CounterPoint Options first launched, it was focused solely on trading the VIX, commonly known as the “fear index.” When traders start buying up put options as “portfolio insurance,” the VIX spikes — a phenomenon that we’ll either trade directly, or use to inform our ETF trades on specific slices of the market. Our agile (and highly lucrative) strategy lets us turn volatility into profits… just like professional traders and hedge funds have been doing for years.

CounterPoint Options helps individual traders make steady, consistent profits from a very methodical approach to growing your portfolio in the midst of a turbulent market.

A pioneer in the development of stock-rating systems and screening software, Jon Markman is co-inventor on two Microsoft patents and author of the best-selling books Swing Trading and Online Investing. He was portfolio manager and senior investment strategist at a multi-strategy hedge fund from 2002 to 2005; managing editor and columnist at CNBC on MSN Money from 1997 to 2002; and an editor, investment columnist and investigative reporter at the Los Angeles Times from 1984 to 1997.

Jon won a Gerald Loeb Award for Distinguished Financial Journalism for his columns explaining market chicanery in 2002; Society of Professional Journalists awards for his 2001 reporting on Enron and the post-Sept. 11-investment environment; and was a news editor on the Los Angeles Times staff that won Pulitzer Prizes for spot-news reporting in 1992 and 1994.

A graduate of Duke University and the Columbia University Graduate School of Journalism, Jon speaks frequently on investment topics at conferences nationwide, as well as on TV and radio.

Recent Articles

Buy Altera (ALTR) on Dips

Stocks rose last week at a peppy pace once investors discovered that the 820 level of the S&P 500 appeared to provide a firm foundation. In a bouncy span of six days, the Dow Jones Industrials and S&P 500 rose 5%, the S&P Smallcap 600 rose 6%, the S&P Midcap 400 rose 6% and the Nasdaq 100 rose 8%.

AstraZeneca’s Big Fat Dividend. Play it Safe

The strongest leadership in the market this year is coming from the drug sector. Let's take a quick look at one: AstraZeneca (AZN).

Will Government Intervention Be Enough?

Merrill Lynch economist David Rosenberg is pulling no punches these days. He says his research shows that we are in the midst of a full-on depression that cannot be thwarted by government intervention.

Numbers Game: Economy Weaker Than Reported

Sentiment is tense, investors are antsy, fundamentals are weak and volume trends are poor. At times like these, bulls will grasp for straws, and that is when they look at the economy for help.

Bad Bank a Bad Idea. Still Not Out of the Woods

At the risk of stating the obvious, the world economic system is in a hell of a fix due to the impact of so many loans gone bad, and it's not just because two of the biggest banks in England and the United States this week suffered another public beating.